Published in J Virol on April 01, 2001
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol (2001) 4.27
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol (2003) 4.11
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Structures of immature flavivirus particles. EMBO J (2003) 3.62
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol (2002) 2.66
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol (2005) 1.88
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol (2004) 1.81
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
The structural immunology of antibody protection against West Nile virus. Immunol Rev (2008) 1.63
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol (2011) 1.51
Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J (2005) 1.41
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol (2012) 1.25
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J Clin Microbiol (2004) 1.11
On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol (2009) 1.11
Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res (2008) 1.09
Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses. J Clin Microbiol (2004) 1.03
A High-Performance Multiplex Immunoassay for Serodiagnosis of Flavivirus-Associated Neurological Diseases in Horses. Biomed Res Int (2015) 0.99
Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol (2010) 0.95
A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice. PLoS One (2012) 0.94
Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines (2012) 0.93
Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice. J Virol (2003) 0.90
Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. Clin Vaccine Immunol (2007) 0.89
Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol (2002) 0.89
Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J (2010) 0.89
Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone. J Virol (2001) 0.88
The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol (2013) 0.86
NMR solution structure and backbone dynamics of domain III of the E protein of tick-borne Langat flavivirus suggests a potential site for molecular recognition. Protein Sci (2006) 0.85
Mutagenesis analysis of T380R mutation in the envelope protein of yellow fever virus. Virol J (2014) 0.82
Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology (2012) 0.81
Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol (2004) 0.80
Inhibition of the Hantavirus Fusion Process by Predicted Domain III and Stem Peptides from Glycoprotein Gc. PLoS Negl Trop Dis (2016) 0.79
Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. Int J Mol Sci (2012) 0.79
Thioaptamers targeting dengue virus type-2 envelope protein domain III. Biochem Biophys Res Commun (2014) 0.77
Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice. BMC Infect Dis (2016) 0.75
Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo. J Antivir Antiretrovir (2009) 0.75
Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design. J Virol (2017) 0.75
A multiplex ELISA-based protein array for screening diagnostic antigens and diagnosis of Flaviviridae infection. Eur J Clin Microbiol Infect Dis (2015) 0.75
SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis (1997) 57.27
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
Phylogeny of the genus Flavivirus. J Virol (1998) 8.87
Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature (1988) 8.32
Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A (1994) 7.76
Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med (1997) 6.57
Calculation of protein conformation from circular dichroism. Methods Enzymol (1986) 5.68
Boundary analysis in sedimentation transport experiments: a procedure for obtaining sedimentation coefficient distributions using the time derivative of the concentration profile. Anal Biochem (1992) 4.94
Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus. J Virol (1984) 3.11
Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol (2000) 1.77
Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology (1998) 1.28
Yellow fever vaccines. Biologicals (1997) 1.17
Towards a new generation of flavivirus vaccines. Vaccine (1994) 1.10
Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol (2000) 1.06
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology (1999) 1.03
Japanese encephalitis and dengue vaccines. Biologicals (1997) 0.94
Flavivirus vaccines. Vaccine (1988) 0.90
Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum (1977) 9.14
SWINE INFLUENZA : II. A HEMOPHILIC BACILLUS FROM THE RESPIRATORY TRACT OF INFECTED SWINE. J Exp Med (1931) 9.13
NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA. J Exp Med (1936) 8.25
Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06
Treatment of hypertension with ascorbic acid. Lancet (1999) 4.74
Neurologic abnormalities of Lyme disease. Medicine (Baltimore) (1979) 3.98
THE ETIOLOGY OF SWINE INFLUENZA. Science (1931) 3.88
AN INTERMEDIATE HOST FOR THE SWINE INFLUENZA VIRUS. Science (1939) 3.87
Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol (2000) 3.21
"MAD ITCH" OF CATTLE. Science (1930) 2.90
The schism between experimental and applied behavior analysis: Is it real and who cares? Behav Anal (1981) 2.87
Two African viruses serologically and morphologically related to rabies virus. J Virol (1970) 2.62
Bunyaviridae. Intervirology (1980) 2.53
Thottapalayam virus: a presumptive arbovirus isolated from a shrew in India. Indian J Med Res (1971) 2.52
Oligonucleotide fingerprints of RNA species obtained from rhabdoviruses belonging to the vesicular stomatitis virus subgroup. J Virol (1977) 2.35
An activities index for use with stroke patients. Age Ageing (1983) 2.31
Phylogeny of the Simbu serogroup of the genus Bunyavirus. J Gen Virol (2001) 2.30
PSEUDORABIES AS A CONTAGIOUS DISEASE IN SWINE. Science (1934) 2.27
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Detection of antibodies to alphaviruses by enzyme-linked immunosorbent assay. J Clin Microbiol (1979) 2.01
Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus. Intervirology (1980) 1.98
Stroke: social and emotional outcome. J R Coll Physicians Lond (1982) 1.96
Venezuelan haemorrhagic fever. Lancet (1991) 1.90
Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation (2001) 1.89
Iron chelation improves endothelial function in patients with coronary artery disease. Circulation (2001) 1.88
Formation of recombinants between snowshoe hare and La Crosse bunyaviruses. J Virol (1977) 1.87
Epidemiological aspects of the 1969 yellow fever epidemic in Nigeria. Bull World Health Organ (1972) 1.86
Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83
Genetic and antigenic diversity among eastern equine encephalitis viruses from North, Central, and South America. Am J Trop Med Hyg (1999) 1.83
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
THE ANTIBODY RESPONSE TO SWINE INFLUENZA. J Exp Med (1939) 1.77
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Genetic variation in the 3' non-coding region of dengue viruses. Virology (2001) 1.71
Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. J Gen Virol (2000) 1.70
Electron microscopic and antigenic studies of uncharacterized viruses. II. Evidence suggesting the placement of viruses in the family Bunyaviridae. Arch Virol (1989) 1.67
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol (2000) 1.64
An antiviral substance from Penicillium funiculosum. V. Induction of interferon by helenine. J Exp Med (1966) 1.63
Detection of La Crosse arbovirus antigen in mosquito pools: application of chromogenic and fluorogenic enzyme immunoassay systems. J Clin Microbiol (1982) 1.62
A CHANGE IN RABBIT FIBROMA VIRUS SUGGESTING MUTATION : III. INTERPRETATION OF FINDINGS. J Exp Med (1936) 1.61
Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol (2001) 1.59
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol (1986) 1.55
Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. Virology (1996) 1.53
Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. J Gen Virol (1985) 1.50
Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol (2001) 1.47
Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis (1995) 1.46
Recurrence of Rift Valley fever in Egypt. Lancet (1993) 1.44
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol (1995) 1.44
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43
An antiviral substance from Penicillium funiculosum. IV. Inquiry into the mechanism by which helenine exerts its antiviral effect. J Exp Med (1966) 1.40
Attenuation of virulence of a bunyavirus involving an L RNA defect and isolation of LAC/SSH/LAC and LAC/SSH/SSH reassortants. Virology (1981) 1.39
Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension (2001) 1.38
Maternal immunity to infectious bovine rhinotracheitis and bovine viral diarrhea viruses: duration and effect on vaccination in young calves. Am J Vet Res (1978) 1.35
Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation (1999) 1.34
Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry (1999) 1.34
Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. Virology (1998) 1.30
Rapid identification of flaviviruses based on conserved NS5 gene sequences. J Virol Methods (1993) 1.30
Serological relation between Rift Valley fever virus and viruses of phlebotomus fever serogroup. Lancet (1980) 1.29
Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology (1995) 1.29
Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol (1995) 1.29
Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology (1998) 1.28
Antigenic relationships among rhabdoviruses from vertebrates and hematophagous arthropods. Intervirology (1989) 1.26
A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology (1992) 1.24
Virulence and viremia characteristics of 1992 epizootic subtype IC Venezuelan equine encephalitis viruses and closely related enzootic subtype ID strains. Am J Trop Med Hyg (2001) 1.23
Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses. Virology (1982) 1.23
Improved clarity of meaning from the use of both formal species names and common (vernacular) virus names in virological literature. Arch Virol (2002) 1.22
Mayaro virus fever in French Guiana: isolation, identification, and seroprevalence. Am J Trop Med Hyg (1998) 1.22
The spread of Rift Valley fever and approaches to its control. Bull World Health Organ (1982) 1.22
Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever. Am J Trop Med Hyg (1994) 1.21
Improved sweat test method for the diagnosis of cystic fibrosis. Arch Dis Child (1984) 1.20
Jatobal virus is a reassortant containing the small RNA of Oropouche virus. Virus Res (2001) 1.20
Evaluation of vero cell lysate antigen for the ELISA of flaviviruses. J Clin Lab Anal (1993) 1.19
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine (2000) 1.15
Enzyme-linked immunosorbent assay for detection of antibodies to Rift Valley fever virus in ovine and bovine sera. Am J Vet Res (1987) 1.15
Molecular epidemiological studies of veterinary arboviral encephalitides. Vet J (1999) 1.15
Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice. J Gen Virol (1995) 1.13
Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol (1986) 1.13
Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J Gen Virol (1994) 1.11
Molecular basis of bunyavirus transmission by mosquitoes: role of the middle-sized RNA segment. Science (1981) 1.11
Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol (1988) 1.10
Elevated stress hormone levels relate to Epstein-Barr virus reactivation in astronauts. Psychosom Med (2001) 1.08
The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay. Am J Trop Med Hyg (1991) 1.08
Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine (1999) 1.08
THE DISTRIBUTION OF SWINE INFLUENZA VIRUS IN SWINE. J Exp Med (1935) 1.07
Role of the middle-sized bunyavirus RNA segment in mouse virulence. Virology (1981) 1.07
West Nile virus strains differ in mouse neurovirulence and binding to mouse or human brain membrane receptor preparations. Ann N Y Acad Sci (2001) 1.07
Rhabdoviridae. Report of the Rhabdovirus Study Group, International Committee on Taxonomy of Viruses. Intervirology (1979) 1.07
Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine (2001) 1.07
Venezuelan equine encephalomyelitis virus structure and its divergence from old world alphaviruses. J Virol (2001) 1.07
Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology (1997) 1.07